Lexaria Bioscience
LEXX
27 hedge funds and large institutions have $3.25M invested in Lexaria Bioscience in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4% less funds holding
Funds holding: 28 → 27 (-1)
7.62% less ownership
Funds ownership: 14.37% → 6.75% (-7.6%)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
43% less capital invested
Capital invested by funds: $5.72M → $3.25M (-$2.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$113K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.1K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$44.5K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$41.4K |
| 5 |
HF
HRT Financial
New York
|
+$32.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.84M |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$120K |
| 3 |
Renaissance Technologies
New York
|
-$63.4K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$12.4K |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$7.47K |
LEXX Hedge Fund Activity: Q3 2024 in Review
27 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q3 2024, worth a combined $3.25M — down 43% from $5.72M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of LEXX and 6 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $113K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.84M sold.
- 27 institutional investors held Lexaria Bioscience (LEXX) as of Q3 2024, down from 28 in Q2 2024.
- Funds reported $3.25M of Lexaria Bioscience stock for Q3 2024, down 43% quarter-over-quarter.
- 6 funds opened new Lexaria Bioscience positions in Q3 2024 and 7 closed out, a net change of -1 holder.
- The largest Lexaria Bioscience buyer in Q3 2024 was Geode Capital Management, an estimated $113K added.
- The largest Lexaria Bioscience seller in Q3 2024 was Armistice Capital, an estimated $2.84M sold.
Based on aggregated 13F filings for Q3 2024.